Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0024623 (gastric cancer)
 36,219 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

This clinical study was undertaken in order to evaluate the effect of CDDP on 43 patients with far-advanced or recurrent carcinoma of the gastrointestinal tract. For all these patients, CDDP at 100 mg/m2 had been administered by continuous intravenous infusion for 24 hours and repeated one to seven times at an interval of 3 to 4 weeks. The effect of this therapy was assessed according to the criteria of clinical evaluation of chemotherapy for solid cancers by Koyama and Saito. The response rate for both complete and partial response was 27.9% among all 43 patients, including 47.1% (8/17) for gastric cancer, 33.3% (1/3) for esophageal cancer, 25.0% (1/4) for hepatocellular carcinoma, 25.0% (1/4) for carcinoma of the gallbladder or bile duct, 20.0% (1/5) for pancreatic cancer and none (0/10) for colorectal cancer. In particular, a good response rate of 37.5% (3/8) was obtained for patients with recurrent tumor and one of 33.3% (6/18) for those with palliative resection of the primary tumor, which was much higher that the rate of 17.6% (3/17) for those without resection. As for the side effects of CDDP therapy, gastrointestinal symptoms were most frequently found in 78.3% of patients followed by bone marrow suppression in 15.2%, and abnormalities of hepatic and renal function in 4.3% and 4.3%, respectively. Consequently, 24-hour continuous intravenous infusion of CDDP was considered to be effective for far-advanced or recurrent carcinoma, especially in cases of gastric cancer.
 ...
PMID:[Clinical study on the effect of 24-hour continuous intravenous infusion of CDDP in far-advanced and recurrent carcinoma of the gastrointestinal tract]. 303 10

High-molecular-weight DNAs from 43 human primary tumor tissues were examined by Southern blot hybridization for possible rearrangement and/or amplification of the following protooncogenes: the c-myc, c-erbB-1, N-myc, c-mos and c-fos genes. In an adenosquamous cell carcinoma of the stomach, the c-myc and c-erbB-1 genes were found to be simultaneously amplified 5- and 30-fold, respectively. Cooperative expression of the amplified c-myc and c-erbB-1 genes might be involved in the genesis or progression of the gastric cancer.
 ...
PMID:DNA amplification of the c-myc and c-erbB-1 genes in a human stomach cancer. 310 22

Based upon our clinical results indications of intraoperative radiotherapy (IORT) for gastric cancer were summarized as follows: (a) The primary tumor must be surgically removed. (b) There must be no metastases to the liver or peritoneum. (c) Serosal invasion must be limited to the posterior wall of the stomach. IORT is not adaptable to patients in whom there is direct invasion of the peritoneum beyond the anterior wall because of the ease of peritoneal dissemination. (d) All unresectable lesions must be encompassed by a single radiation field. (e) No significant difference between cumulative survival of patients with Stage I gastric cancer who were treated by IORT or surgery alone was found. Therefore IORT may be of no benefit to the prognosis of patients with Stage I gastric cancer. As for the IORT dose, it is recommended that for clinically undetectable lesions a single dose of 28 Gy be delivered. For macroscopic remnants 30-35 Gy should be delivered depending upon the residual tumor size. The electron energy is selected so that the entire lesion is included by the 90% isodose line. When IORT is applied to a curative operation, the radiation field is positioned toward the lymph node groups around the celiac axis, which are hard to eliminate by a surgical procedure.
 ...
PMID:Japan gastric trials in intraoperative radiation therapy. 319 40

We have determined the prevalence of pepsinogen II (PG II) immunoreactive cells in a large series of early and advanced gastric cancers and relationships among PG II-positivity, tumor histologic type, extent of gastric wall invasion, and presence of lymph node metastases. Of the 316 cancers evaluated, 150 (47%) expressed PG II. The prevalence by histologic type was 55% in 146 glandular tumors, 43% in 83 diffuse tumors, 16% in 25 mucoid tumors, and 51% in 59 mixed-type cancers. Two parietal cell cancers and one undifferentiated cancer were PG II-negative. In glandular and diffuse cancers, but not mucoid and mixed tumors, both the extent of gastric wall invasion and incidence of lymph node metastases were associated positively with PG II expression by the primary tumor. In particular, PG II-reactive cells were found significantly more often in advanced than in early diffuse cancers (P less than 0.05) and significantly more often in submucosal early cancers than in intramucosal early cancers (P less than 0.01). The prevalence of PG II expression also was higher significantly in metastatic cancers than in nonmetastatic cancers. This was true for advanced gastric cancers as a whole (P less than 0.01), advanced glandular-type cancer alone (P less than 0.01), advanced glandular- and diffuse- type cancers together (P less than 0.001), and early diffuse-type cancer (P less than 0.05). Only four (3%) of 145 cancers evaluated for pepsinogen I (PG I) were positive, and each also was positive for PG II. The results suggest that the expression of PG II by glandular and diffuse types of gastric cancer may be a marker of increased malignancy.
 ...
PMID:Expression of pepsinogen II in gastric cancer. Its relationship to local invasion and lymph node metastases. 333 59

Two hundred and forty-two patients who underwent curative surgery for primary gastric cancer between 1965 and 1979 were reviewed, and the influence on survival of the type of surgical treatment, primary tumor location, operative mortality, and stage of disease was analyzed. Operative mortality was significantly increased in patients with multicentric primaries compared to all other sites (P less than .001) and in patients undergoing total gastrectomy versus subtotal gastric resection (P less than 0.001). Stage III-IV lesions had a significantly worse prognosis than stage I-II tumors (P less than .001). Our data confirm that early diagnosis could lead to increased survival.
 ...
PMID:Factors influencing survival in 242 cases of primary gastric carcinoma. 337 45

Seventy-five cases of metastatic skin cancers, collected from 15 institutions in West Japan, were included in this study. The most frequently occurring primary tumors were carcinoma of the lung (31%) and carcinoma of the stomach (20%). Metastatic lesions of lung cancer were common on the neck, face and scalp. The anterior part of the abdomen was the most common metastatic site for stomach cancer. The average interval between the appearance of the skin lesion and the detection of the primary cancer was 20 months. Of 23 patients with lung cancer, and of 15 patients with stomach cancer, cutaneous metastasis preceded documentation of the primary tumor in 10 cases of lung cancer and 4 cases of stomach cancer. Three of these 4 cases were signet ring cell carcinoma. The average survival after the development of cutaneous metastasis was 11 months. In 13 cases of lung cancer, it was 4.7 months. The average interval between the appearance of skin lesions and death in 3 patients with squamous cell carcinoma of the lung was 0.8 months.
 ...
PMID:[Statistical study of metastatic skin cancer--interrelation of the origin of primary tumor, metastatic skin lesions, prognosis and histopathology]. 338 29

The purposes of this administration were to inactivate cancer cells liberated from the primary tumor, to prevent them from metastasizing to other organs and to treat established metastatic cancer. Sixty-one patients with advanced gastric cancer who had received preoperative 5-FU dry syrup administration and who had also undergone curative resection between 1976 and 1982, in addition to postoperative chemotherapy (more than 20 mg MMC, 5,000 mg 5-FU), (Group A) were admitted to the present study. Their survival rate was compared with that of 67 patients given curative resection for advanced cancer without preoperative 5-FU dry syrup, who received the same postoperative chemotherapy only (Group B) during the same period. The 5-year survival rate for Group A was 0.55 +/- 0.06, higher than the rate of 0.42 +/- 0.06 for Group B. Comparing the 5-year survival rates of both groups in terms of clinicopathological factors such as stage of cancer progression, serosal invasion, lymph node metastasis, and lymphangitic and blood vessel invasion, the 5-year survival rates for Group A were higher than those for Group B. There were significant differences for histological stage III and blood vessel invasion between the two groups. From these results, it is suggested that preoperative oral 5-FU dry syrup might be effective as an adjuvant therapy to surgery for gastric cancer.
 ...
PMID:[End result of preoperative adjuvant chemotherapy with oral 5-FU dry syrup in gastric cancer]. 338 42

The significance of primary tumor resection in gastric and colorectal cancer patients with liver metastasis (H(+)) was evaluated in terms of operative mortality and survival rate by dividing the materials [293 gastric cancer and 80 colorectal cancer patients (53 colon and 27 rectum) with synchronous liver metastasis] into the following groups: Firstly, with or without peritoneal dissemination (P), secondly, with or without resection of the primary tumor and thirdly, with or without postoperative adjuvant chemotherapy. The following results were obtained: (1) The direct operative death rate of primary tumor resection, excluding death from other causes, showed an absence of statistically significant differences between the P0H(+) and P(+)H(+) gastric and colorectal cancer patients. (2) There was no significance in the prognosis between the primary tumor resection + postoperative chemotherapy group and the non-resectable group in the P(+)H(+) gastric and colorectal cancer patients, revealing no prognostic value of the primary tumor. (3) In the P0H(+) gastric and colorectal cancer patients, the primary tumor resection + postoperative chemotherapy group was significantly more favorable in prognosis than was the primary tumor resection alone group or the non-resectable group, showing the value of primary tumor resection.
 ...
PMID:The prognostic significance of resection of primary tumor in gastric and colorectal cancer patients with synchronous liver metastasis. 338 73

Metastatic mode of gastric cancer was examined in 173 autopsy cases, in which the primary tumor had not been resected, and was compared between different histological types as well as different age groups. From the histological view point, the differentiated gastric cancer showed preferential metastasis to the liver, while the undifferentiated type showed a prevalence in peritoneal dissemination as well lymph node metastasis. From the view point of aging, the peritoneal dissemination was more frequently observed in the younger patients than in the older patients in both differentiated and undifferentiated types. The similar prevalence in the younger patients was also observed in lymph node metastasis of gastric cancer of undifferentiated type, but not in that of differentiated type. Regarding the liver metastasis, there was no difference between different age groups in both differentiated and undifferentiated types.
 ...
PMID:[Differential metastatic mode of gastric cancer by age and histological type]. 358 22

We have examined the level of the c-myc transcript in 6 esophageal, 16 gastric, 19 colorectal and 1 anal cancer tissue samples; these included four lymph nodes and six hepatic metastases obtained surgically. The esophageal cancer tissues were without an increase of the c-myc transcript, some of the gastric cancer samples showed a two to three fold increase and most of the colorectal and the one anal cancer samples showed a two to ten fold increase when compared with a normal mucosal layer. Therefore, the level of the c-myc transcript in human gastrointestinal malignancies shows organ dependency. Local, lymphatic, and hepatic metastases showed little difference in the level of c-myc mRNA from that of the primary tumor.
 ...
PMID:Expression of the c-myc gene in human gastrointestinal malignancies. 361 99


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>